<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005602</url>
  </required_header>
  <id_info>
    <org_study_id>ACCP 2006-07</org_study_id>
    <secondary_id>2008-05762</secondary_id>
    <nct_id>NCT01005602</nct_id>
  </id_info>
  <brief_title>Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care</brief_title>
  <official_title>Use of a Simplified Nomogram and Pharmacogenetics to Individualize Digoxin Dosing in Heart Failure Patients vs. Standard Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Clinical Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dosing methods for digoxin, a drug used to treat heart failure, have not been updated in
      decades despite evidence in recent years suggesting that blood levels of digoxin achieved
      with traditional dosing practices may increase the risk of adverse events. We developed a
      simple dosing tool that targets lower blood levels of digoxin that have been associated with
      improved outcomes compared to higher blood levels. The aim of this study is to determine if
      this simplified dosing tool is more effective than standard digoxin dosing practices at
      achieving lower blood levels and also to determine if digoxin dosing may be further optimized
      by incorporating patients' genetic information believed to influence the drug's properties.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Digoxin is recommended as adjunctive therapy in patients with left ventricular dysfunction
      and symptoms of heart failure despite treatment with standard therapy. Recently, the
      therapeutic range for digoxin in patients with heart failure has been redefined to a narrower
      therapeutic window (0.5 - 0.9 ng/ml) because lower serum levels in this range have been
      associated with improved survival whereas higher serum levels have been associated with
      increased mortality. However, dosing methods have not been updated to reflect the newly
      defined therapeutic range for digoxin. We developed a simplified dosing nomogram for digoxin
      in patients with heart failure designed to achieve serum digoxin concentrations (SDC) within
      the new therapeutic range using retrospective data. The long-term goal of this study is to
      prospectively validate the ability of our digoxin dosing nomogram to achieve desired SDC and
      provide clinicians a simplified tool to optimize digoxin dosing in patients with heart
      failure. Because digoxin is a substrate of the efflux pump p-glycoprotein (pGP) and genetic
      polymorphisms of the MDR1 gene (known to regulate pGP expression) have demonstrated
      conflicting results on the pharmacokinetic profile of digoxin, we will also characterize the
      influence MDR1 functional gene variants may have on digoxin dosing. This study will include a
      total of 170 subjects with symptomatic heart failure treated with digoxin, comparing
      steady-state SDC in a prospective group of patients dosed according to our nomogram to a
      historical control group in whom the dose of digoxin was derived from standard dosing
      practices. We will also conduct an analysis of genetic polymorphisms of the MDR1 gene known
      to affect digoxin pharmacokinetics. The primary objectives of the study are to compare the
      percentage of patients in each group achieving steady-state SDC within the desired range of
      0.5 - 0.9 ng/ml, characterize the relationship between genetic variability in the MDR1 gene
      and digoxin dosing, and to update our digoxin dosing nomogram to account for the clinical and
      genetic variability shown to have the greatest influence on digoxin dosing. The rationale for
      this study is that lower doses of digoxin are recommended because lower SDC are associated
      with improved survival. Therefore, digoxin dosing methods must be updated to reflect these
      recommendations and account for genetic variability of the MDR1 gene in an effort to improve
      clinical outcomes and minimize the potential for adverse events. To address these issues, the
      specific aims of this research are:

      Aim 1: Compare steady-state SDC observed using our dosing nomogram to those obtained using
      standard dosing practices.

      Aim 2: Characterize the relationship of the genetic variability of the MDR1 gene and SDC
      observed using our digoxin dosing nomogram.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Patients Achieving a Desired Steady-state Serum Digoxin Concentration Between 0.5 - 0.9ng/ml</measure>
    <time_frame>Steady-state (2 - 4 weeks after initiation)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Digoxin Concentration</measure>
    <time_frame>Steady-state (2 - 4 weeks after initiation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Digoxin Concentration &lt; 1.0 ng/ml</measure>
    <time_frame>Steady-state (2 - 4 weeks after initiation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Digoxin Concentration by ABCB1 Single Nucleotide Polymorphism (SNP) C1236T</measure>
    <time_frame>Steady-state (2 - 4 weeks after initiation)</time_frame>
    <description>55 patients in the Digoxin Dosing per Nomogram group consented to the Pharmacogenetic substudy and provided blood samples to perform pharmacogenetic analyses. We compared serum digoxin concentrations by ABCB1 genotype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Digoxin Concentration by ABCB1 SNP C3435T</measure>
    <time_frame>Steady-state (2 - 4 weeks after initiation)</time_frame>
    <description>Serum digoxin concentration by genotypes for the ABCB1 SNP C3435T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Digoxin Concentration by ABCB1 SNP G2677T/A</measure>
    <time_frame>Steady-state (2 - 4 weeks after initiation)</time_frame>
    <description>Serum digoxin concentration by ABCB1 SNP genotypes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Digoxin Dosing per Nomogram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have their digoxin maintenance dose determined according to the nomogram we have developed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Digoxin Dosing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm represents historical control subjects in whom the dose of digoxin was determined at the physician's discretion using traditional dosing methods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Digoxin Dosing per Nomogram</intervention_name>
    <description>Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).</description>
    <arm_group_label>Digoxin Dosing per Nomogram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.</description>
    <arm_group_label>Digoxin Dosing per Nomogram</arm_group_label>
    <arm_group_label>Standard Digoxin Dosing</arm_group_label>
    <other_name>Lanoxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 21 years

          -  Diagnosis of heart failure secondary to left ventricular dysfunction

          -  Receiving chronic digoxin therapy or digoxin therapy is being initiated

        Exclusion Criteria:

          -  Pregnant

          -  Unstable renal function, defined as either a rise in serum creatinine by &gt; 0.5mg/dl
             from baseline or a decrease in creatinine clearance by 25% or more within two to four
             weeks of study entry.

          -  End-stage renal disease requiring hemodialysis

          -  Concomitant therapy with drugs known to interact with digoxin (e.g., amiodarone,
             quinidine, verapamil, macrolide antibiotics)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J DiDomenico, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bauman JL, DiDomenico RJ, Viana M, Fitch M. A method of determining the dose of digoxin for heart failure in the modern era. Arch Intern Med. 2006 Dec 11-25;166(22):2539-45. Erratum in: Arch Intern Med. 2007 Mar 12;167(5):496. Dosage error in article text.</citation>
    <PMID>17159022</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2009</study_first_submitted>
  <study_first_submitted_qc>October 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2009</study_first_posted>
  <results_first_submitted>April 16, 2014</results_first_submitted>
  <results_first_submitted_qc>April 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2014</results_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Robert J. DiDomenico</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Digoxin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Dosing</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Digoxin Dosing Per Nomogram</title>
          <description>Subjects will have their digoxin maintenance dose determined according to the nomogram we have developed.
Dosing nomogram for digoxin: Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).</description>
        </group>
        <group group_id="P2">
          <title>Standard Digoxin Dosing</title>
          <description>This arm represents historical control subjects in whom the dose of digoxin was determined at the physician's discretion using traditional dosing methods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65">One patient completed the trial but was excluded from data analyses due to unreliable clinical data.</participants>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Excluded due to unreliable clinical data</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Digoxin Dosing Per Nomogram</title>
          <description>Subjects will have their digoxin maintenance dose determined according to the nomogram we have developed.
Dosing nomogram for digoxin: Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).</description>
        </group>
        <group group_id="B2">
          <title>Standard Digoxin Dosing</title>
          <description>This arm represents historical control subjects in whom the dose of digoxin was determined at the physician's discretion using traditional dosing methods.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="131"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="15"/>
                    <measurement group_id="B2" value="63" spread="15"/>
                    <measurement group_id="B3" value="60" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ideal body weight</title>
          <description>Ideal body weight (IBW) as determined by the method of Devine. (Devine BJ. Drug Intell Clin Pharm 1974;8:650-5.)</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="10"/>
                    <measurement group_id="B2" value="62" spread="11"/>
                    <measurement group_id="B3" value="65" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100" spread="34"/>
                    <measurement group_id="B2" value="85" spread="27"/>
                    <measurement group_id="B3" value="92" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="10.4"/>
                    <measurement group_id="B2" value="29.9" spread="8.9"/>
                    <measurement group_id="B3" value="31.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine clearance</title>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="10"/>
                    <measurement group_id="B2" value="51" spread="22"/>
                    <measurement group_id="B3" value="58" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated Glomerular Filtration Rate</title>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="22"/>
                    <measurement group_id="B2" value="59" spread="23"/>
                    <measurement group_id="B3" value="65" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Patients Achieving a Desired Steady-state Serum Digoxin Concentration Between 0.5 - 0.9ng/ml</title>
        <time_frame>Steady-state (2 - 4 weeks after initiation)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Digoxin Dosing Per Nomogram</title>
            <description>Subjects will have their digoxin maintenance dose determined according to the nomogram we have developed.
Dosing nomogram for digoxin: Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).</description>
          </group>
          <group group_id="O2">
            <title>Standard Digoxin Dosing</title>
            <description>This arm represents historical control subjects in whom the dose of digoxin was determined at the physician's discretion using traditional dosing methods.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Achieving a Desired Steady-state Serum Digoxin Concentration Between 0.5 - 0.9ng/ml</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Digoxin Concentration</title>
        <time_frame>Steady-state (2 - 4 weeks after initiation)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Digoxin Dosing Per Nomogram</title>
            <description>Subjects will have their digoxin maintenance dose determined according to the nomogram we have developed.
Dosing nomogram for digoxin: Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).</description>
          </group>
          <group group_id="O2">
            <title>Standard Digoxin Dosing</title>
            <description>This arm represents historical control subjects in whom the dose of digoxin was determined at the physician's discretion using traditional dosing methods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Digoxin Concentration</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.30"/>
                    <measurement group_id="O2" value="1.12" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Digoxin Concentration &lt; 1.0 ng/ml</title>
        <time_frame>Steady-state (2 - 4 weeks after initiation)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Digoxin Dosing Per Nomogram</title>
            <description>Subjects will have their digoxin maintenance dose determined according to the nomogram we have developed.
Dosing nomogram for digoxin: Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).</description>
          </group>
          <group group_id="O2">
            <title>Standard Digoxin Dosing</title>
            <description>This arm represents historical control subjects in whom the dose of digoxin was determined at the physician's discretion using traditional dosing methods.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Digoxin Concentration &lt; 1.0 ng/ml</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2"/>
                    <measurement group_id="O2" value="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Digoxin Concentration by ABCB1 Single Nucleotide Polymorphism (SNP) C1236T</title>
        <description>55 patients in the Digoxin Dosing per Nomogram group consented to the Pharmacogenetic substudy and provided blood samples to perform pharmacogenetic analyses. We compared serum digoxin concentrations by ABCB1 genotype.</description>
        <time_frame>Steady-state (2 - 4 weeks after initiation)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wild Type</title>
            <description>Genotypes for the ABCB1 single nucleotide polymorphism C1236T</description>
          </group>
          <group group_id="O2">
            <title>CT Genotype</title>
          </group>
          <group group_id="O3">
            <title>TT Genotype</title>
          </group>
        </group_list>
        <measure>
          <title>Serum Digoxin Concentration by ABCB1 Single Nucleotide Polymorphism (SNP) C1236T</title>
          <description>55 patients in the Digoxin Dosing per Nomogram group consented to the Pharmacogenetic substudy and provided blood samples to perform pharmacogenetic analyses. We compared serum digoxin concentrations by ABCB1 genotype.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.27"/>
                    <measurement group_id="O2" value="0.56" spread="0.37"/>
                    <measurement group_id="O3" value="0.58" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Digoxin Concentration by ABCB1 SNP C3435T</title>
        <description>Serum digoxin concentration by genotypes for the ABCB1 SNP C3435T</description>
        <time_frame>Steady-state (2 - 4 weeks after initiation)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wild Type (CC)</title>
          </group>
          <group group_id="O2">
            <title>CT Genotype</title>
          </group>
          <group group_id="O3">
            <title>TT Genotype</title>
          </group>
        </group_list>
        <measure>
          <title>Serum Digoxin Concentration by ABCB1 SNP C3435T</title>
          <description>Serum digoxin concentration by genotypes for the ABCB1 SNP C3435T</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.28"/>
                    <measurement group_id="O2" value="0.54" spread="0.35"/>
                    <measurement group_id="O3" value="0.46" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Digoxin Concentration by ABCB1 SNP G2677T/A</title>
        <description>Serum digoxin concentration by ABCB1 SNP genotypes</description>
        <time_frame>Steady-state (2 - 4 weeks after initiation)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wild Type (GG)</title>
          </group>
          <group group_id="O2">
            <title>GT Genotype</title>
          </group>
          <group group_id="O3">
            <title>TT Genotype</title>
          </group>
          <group group_id="O4">
            <title>GA Genotype</title>
          </group>
        </group_list>
        <measure>
          <title>Serum Digoxin Concentration by ABCB1 SNP G2677T/A</title>
          <description>Serum digoxin concentration by ABCB1 SNP genotypes</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.27"/>
                    <measurement group_id="O2" value="0.50" spread="0.42"/>
                    <measurement group_id="O3" value="0.66" spread="0.30"/>
                    <measurement group_id="O4" value="0.40" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Digoxin Dosing Per Nomogram</title>
          <description>Subjects will have their digoxin maintenance dose determined according to the nomogram we have developed.
Dosing nomogram for digoxin: Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).</description>
        </group>
        <group group_id="E2">
          <title>Standard Digoxin Dosing</title>
          <description>This arm represents historical control subjects in whom the dose of digoxin was determined at the physician's discretion using traditional dosing methods.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert J. DiDomenico</name_or_title>
      <organization>University of Illinois at Chicago</organization>
      <phone>(312) 413-4654</phone>
      <email>rdidom1@uic.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

